KR20230163147A - Composition for preventing or treating alopecia comprising extracts of Osmanthus fragrans - Google Patents
Composition for preventing or treating alopecia comprising extracts of Osmanthus fragrans Download PDFInfo
- Publication number
- KR20230163147A KR20230163147A KR1020220062876A KR20220062876A KR20230163147A KR 20230163147 A KR20230163147 A KR 20230163147A KR 1020220062876 A KR1020220062876 A KR 1020220062876A KR 20220062876 A KR20220062876 A KR 20220062876A KR 20230163147 A KR20230163147 A KR 20230163147A
- Authority
- KR
- South Korea
- Prior art keywords
- hair
- extract
- preventing
- hair loss
- loss
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 109
- 201000004384 Alopecia Diseases 0.000 title claims abstract description 41
- 239000000203 mixture Substances 0.000 title claims abstract description 40
- 244000242564 Osmanthus fragrans Species 0.000 title description 7
- 235000019083 Osmanthus fragrans Nutrition 0.000 title description 7
- 231100000360 alopecia Toxicity 0.000 title description 4
- 230000003676 hair loss Effects 0.000 claims abstract description 37
- 208000024963 hair loss Diseases 0.000 claims abstract description 37
- 230000003779 hair growth Effects 0.000 claims abstract description 32
- 230000036541 health Effects 0.000 claims abstract description 31
- 239000002537 cosmetic Substances 0.000 claims abstract description 22
- 235000013376 functional food Nutrition 0.000 claims abstract description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 17
- 210000004209 hair Anatomy 0.000 claims description 77
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 63
- 241000196324 Embryophyta Species 0.000 claims description 18
- 230000001737 promoting effect Effects 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 230000003752 improving hair Effects 0.000 claims description 12
- 230000003658 preventing hair loss Effects 0.000 claims description 12
- -1 hair pack Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 9
- 235000013399 edible fruits Nutrition 0.000 claims description 7
- 238000009472 formulation Methods 0.000 claims description 7
- 239000012046 mixed solvent Substances 0.000 claims description 6
- 239000006071 cream Substances 0.000 claims description 4
- 241000195940 Bryophyta Species 0.000 claims description 3
- 239000008266 hair spray Substances 0.000 claims description 3
- 239000006210 lotion Substances 0.000 claims description 3
- 235000011929 mousse Nutrition 0.000 claims description 3
- 239000002453 shampoo Substances 0.000 claims description 3
- 239000000344 soap Substances 0.000 claims description 3
- 230000001256 tonic effect Effects 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 abstract description 29
- 230000004054 inflammatory process Effects 0.000 abstract description 29
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 26
- 230000002500 effect on skin Effects 0.000 abstract description 18
- 239000003163 gonadal steroid hormone Substances 0.000 abstract description 8
- 210000003780 hair follicle Anatomy 0.000 abstract description 6
- 230000005764 inhibitory process Effects 0.000 abstract description 5
- 238000000605 extraction Methods 0.000 description 33
- 210000004027 cell Anatomy 0.000 description 29
- 230000001939 inductive effect Effects 0.000 description 21
- 210000002540 macrophage Anatomy 0.000 description 21
- 102000010907 Cyclooxygenase 2 Human genes 0.000 description 16
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 16
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 16
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 15
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 15
- 210000004761 scalp Anatomy 0.000 description 14
- 239000002904 solvent Substances 0.000 description 14
- 239000002158 endotoxin Substances 0.000 description 12
- 229920006008 lipopolysaccharide Polymers 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 description 9
- BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 238000003809 water extraction Methods 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 244000178870 Lavandula angustifolia Species 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 239000007884 disintegrant Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 235000013373 food additive Nutrition 0.000 description 4
- 239000002778 food additive Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000009245 menopause Effects 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000000440 bentonite Substances 0.000 description 3
- 229910000278 bentonite Inorganic materials 0.000 description 3
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 229960002986 dinoprostone Drugs 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 235000012041 food component Nutrition 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 239000005417 food ingredient Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000007902 hard capsule Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 238000009806 oophorectomy Methods 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 210000002374 sebum Anatomy 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000002023 wood Substances 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000000748 compression moulding Methods 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 238000000874 microwave-assisted extraction Methods 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 238000000899 pressurised-fluid extraction Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- QIZPVNNYFKFJAD-UHFFFAOYSA-N 1-chloro-2-prop-1-ynylbenzene Chemical compound CC#CC1=CC=CC=C1Cl QIZPVNNYFKFJAD-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- BGWLYQZDNFIFRX-UHFFFAOYSA-N 5-[3-[2-[3-(3,8-diamino-6-phenylphenanthridin-5-ium-5-yl)propylamino]ethylamino]propyl]-6-phenylphenanthridin-5-ium-3,8-diamine;dichloride Chemical compound [Cl-].[Cl-].C=1C(N)=CC=C(C2=CC=C(N)C=C2[N+]=2CCCNCCNCCC[N+]=3C4=CC(N)=CC=C4C4=CC=C(N)C=C4C=3C=3C=CC=CC=3)C=1C=2C1=CC=CC=C1 BGWLYQZDNFIFRX-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241000196133 Dryopteris Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241001071795 Gentiana Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000218922 Magnoliophyta Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 241000120852 Polyommatus phyllis Species 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 230000003656 anti-hair-loss Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000003323 beak Anatomy 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000036576 dermal application Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 241001233957 eudicotyledons Species 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 210000002768 hair cell Anatomy 0.000 description 1
- 230000031774 hair cycle Effects 0.000 description 1
- 230000003803 hair density Effects 0.000 description 1
- 230000003662 hair growth rate Effects 0.000 description 1
- 230000003646 hair health Effects 0.000 description 1
- 210000004919 hair shaft Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 238000010872 live dead assay kit Methods 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 235000019462 natural additive Nutrition 0.000 description 1
- 230000007383 nerve stimulation Effects 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012860 organic pigment Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229940035023 sucrose monostearate Drugs 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940104261 taurate Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000003813 thin hair Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000019195 vitamin supplement Nutrition 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Botany (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Polymers & Plastics (AREA)
- Birds (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medical Informatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 목서 추출물을 포함하는 약학 조성물, 건강기능식품 및 화장료 조성물에 관한 것이다. 본 발명의 목서 추출물은 모유두세포에서 항염증 활성을 가짐으로써, 모낭 내 염증으로 기인된 모발성장 억제를 완화시킬 수 있다. 또한, 본 발명의 목서 추출물은 폐경 여성에서 성호르몬 변화로 기인된 탈모를 예방하고 모발성장을 촉진할 수 있다.The present invention relates to pharmaceutical compositions, health functional foods, and cosmetic compositions containing extracts of the plant. By having anti-inflammatory activity in dermal papilla cells, the extract of the present invention can alleviate hair growth inhibition caused by inflammation within hair follicles. In addition, the Moxa extract of the present invention can prevent hair loss caused by changes in sex hormones and promote hair growth in menopausal women.
Description
본 발명은 목서 추출물의 탈모 방지 및 발모 촉진 효능에 관한 것이다.The present invention relates to the anti-hair loss and hair growth promoting effects of Moxa extract.
인간의 모발은 통상적으로 머리에 난 긴 체모를 지칭하는 것으로 머리에서 자라는 긴 털을 의미하고 있다. 모발은 일종의 쿠션을 형성하여 외부 마찰에 대한 충격을 완화해주고, 모발 사이의 공기층을 형성하여 머리의 온도를 일정하게 유지할 뿐만 아니라 자외선으로부터 두피를 보호하는 역할을 하고 있다. 뿐만 아니라 모발은 중금속을 비롯한 노폐물 배출하는 역할을 담당하고 있다. 모발은 포유동물만이 가지고 있는 단단하게 밀착되고 각화된 상피세포로 이루어진 고형의 원추섬유이며, 두피의 모발 수는 약 10만개 정도로서 출생 시 그 수가 결정되고 출생 후에는 모낭이 새로 생기지 않는다. 모발의 성장속도는 하루에 0.35 mm, 한달에 1 ~ 1.5 cm가 자라며 환경요인에 의해 달라질 수 있다. 모발의 굵기에 따라 경모는 굵은 모발로 0.1m이고, 보통 모발은 0.075 ~0.085 mm로 연모는 가는 모발로써 0.06mm이로 구분되어질 수 있으나 성장부위에 따라 굵기가 달라지게 되는데 일반적으로 모발은 다른 부위보다 대체로 가는 편에 속한다.Human hair generally refers to the long hair growing on the head. Hair forms a kind of cushion to relieve the impact of external friction, and forms an air layer between hairs to not only keep the temperature of the head constant but also protect the scalp from ultraviolet rays. In addition, hair is responsible for excreting waste products, including heavy metals. Hair is a solid conical fiber made up of tightly adhered and keratinized epithelial cells that only mammals have. The number of hairs on the scalp is approximately 100,000, the number of which is determined at birth, and no new hair follicles are formed after birth. Hair growth rate is 0.35 mm per day and 1 to 1.5 cm per month and can vary depending on environmental factors. Depending on the thickness of the hair, terminal hair is thick hair and is 0.1m, normal hair is 0.075 to 0.085 mm, and vellus hair is thin hair and can be classified as 0.06mm, but the thickness varies depending on the growth area. In general, hair is thicker than other areas. It's generally on the thin side.
모발은 피부 내에 있는 모근부와 피부면에서 외부에 나와있는 모간부로 구분된다. 모유두는 모근부의 아래 끝부분으로 혈모세혈관 및 신경이 분포되어 있어 혈액과 모발 사이의 산소와 영양분, 노폐물 순환, 모발의 영양이나 발육 등을 조절하고 있다. 모유두 (Dermal papilla)는 피부 진피 중 모낭 밑 부분에 수많은 혈관조직과 세포로 구성된 유두모양의 돌기로서 모발의 모체에서 세포분열을 통하여 형성된 자세포를 만들어내고 다음 세포의 형성에 의해 자연적으로 위로 밀려 올려가게 된 후 밀려올라간 세포는 모근의 위쪽에서 점진적으로 케라틴 합성을 통하여 모발을 구성하게 되는 모발 성장의 근원이 된다. 이후 모유두에 접하고 있는 부분으로 모발이 자라나는데 있어 주요한 역할을 한다. 모구부의 오목한 부분은 모모세포가 덮고 있는데 세포분열이 왕성하여 끊임없이 분열과 증식을 되풀이하게 됨으로써 모유두에서 영향을 받아 분열하여 모발이 지속적으로 자라게 되며, 많은 사이토카인 (Cytokine)과 성장인자 (Growth factor)들이 관여하여 모발의 성장주기를 결정하게 되며, 기관유지와 더불어 모발의 굵기 및 형태가 결정되게 된다. 모발은 진피 속 털 부리 옆에 있는 입모근 (Arrector pilorum muscle)이 결합조직막 외부에 닿아 있어 이 부분은 교감신경의 지배를 받아 신경자극으로 근육이 수축될 뿐만 아니라 입모근의 수축은 모발 주위에 있는 기름샘을 자극하게 된다. 이러한 자극은 피지선과 연관되어 진피에 있는 분비선으로 지방 분비를 촉진하여 표피와 모발에 윤기, 광택, 유연성 및 탄력성을 주게 된다. 그러나, 이러한 피지의 과다 분출은 모공을 막아 피지의 분출을 억제시켜 모낭 속에 박테리아 서식을 가능케 하여 두피 염증이 발생되게 된다. 이러한 두피염증으로 기인된 두피 열은 두피 장벽 기능저하, 과도한 유분 분비로 기인된 지루성 피부염 및 두피 각질화를 통한 탈모 유발의 원인으로 제기되고 있다.Hair is divided into the hair root within the skin and the hair shaft outside the skin. The dermal papilla is the lower end of the hair root, where blood capillaries and nerves are distributed, controlling the circulation of oxygen, nutrients and waste between blood and hair, and hair nutrition and development. Dermal papilla is a papilla-shaped protrusion composed of numerous vascular tissues and cells at the bottom of the hair follicle in the dermis of the skin. It produces progenitor cells formed through cell division in the hair matrix and is naturally pushed upward by the formation of the next cell. The cells that are pushed up after going become the source of hair growth that forms hair through gradual keratin synthesis above the hair root. Afterwards, it is the part that is in contact with the dermal papilla and plays a major role in hair growth. The concave part of the hair bulb is covered by hair cells, which undergo vigorous cell division and continuously repeat division and proliferation. As a result, the hair papilla divides and grows continuously, producing many cytokines and growth factors. They are involved in determining the hair growth cycle, and along with organ maintenance, the thickness and shape of the hair are determined. In hair, the arrector pilorum muscle next to the beak of the hair in the dermis is in contact with the outside of the connective tissue membrane. This part is under the control of the sympathetic nerve, so not only does the muscle contract due to nerve stimulation, but the contraction of the arrector pilorum muscle also removes the oil around the hair. It stimulates the gland. This stimulation is associated with the sebaceous glands and promotes the secretion of fat into the glands in the dermis, giving shine, luster, flexibility and elasticity to the epidermis and hair. However, this excessive ejection of sebum blocks the pores, suppresses the ejection of sebum, and allows bacteria to colonize in the hair follicles, resulting in scalp inflammation. Scalp heat caused by such scalp inflammation is suggested to be the cause of hair loss through reduced scalp barrier function, seborrheic dermatitis caused by excessive oil secretion, and scalp keratinization.
한편 탈모는 정상적으로 모발이 존재해야되는 부위에 모발이 없는 상태, 또는 성장을 멈춘 모발이 자연스럽게 빠지는 현상으로 일반적으로 모발은 하루에 50-100개 이상 정도가 빠지는 반면, 외부의 자극 또는 내적 요인에 의해 두피로부터 빠지는 모발이 많아지면서 이를 초과하여 모발이 빠지는 경우 탈모증이라고 지칭하게 된다. 이러한 탈모의 원인은 성호르몬의 변화에 따른 신체 내분비기계 이상과 더불어, 정신적 스트레스, 환경오염, 잘못된 식습관, 음주, 흡연, 피부염, 곰팡이 감염, 약물복용 이상 등 다양한 원인들이 복합적으로 작용하여 탈모의 원인으로 제기되고 있으나, 현재까지 근본적인 치료제가 없는 실정이다. 최근 20-30 대 노동 가용 연령층 및 여성에서 탈모질환 증가로 우울증, 구직 및 결혼 등을 포함한 사회생활에서 상당한 부정적 요인으로 작용하고 있음에 따라 이에 대한 효과적인 치료제가의 개발이 필요한 실정이다.Meanwhile, hair loss is a condition in which there is no hair in areas where hair should normally exist, or hair that has stopped growing falls out naturally. Typically, more than 50 to 100 hairs fall out per day, but hair loss occurs due to external stimulation or internal factors. As the amount of hair falling out from the scalp increases and hair loss exceeds this amount, it is referred to as alopecia. The cause of hair loss is a combination of various causes such as mental stress, environmental pollution, incorrect eating habits, drinking, smoking, dermatitis, fungal infection, and abnormal drug use, as well as abnormalities in the body's endocrine system due to changes in sex hormones. However, there is currently no fundamental treatment. Recently, hair loss disease has increased in the working age group and women in their 20s and 30s, which is acting as a significant negative factor in social life, including depression, job search, and marriage. Therefore, there is a need to develop an effective treatment for it.
한편 목서는 식물계, 속씨식물문, 쌍떡잎식물강, 용담목, 물푸레나무과에 속하는 목본성 식물로써 온대 남부수종, 중용수, 내한성에 약해 한국 및 중국 등에 풍부히 서식한다. 목서의 꽃은 2가화로 10-11월에 개화하며 향이 무척 향기로와 우리나라 남부지역에서는 주로 조경수로 활용되고 있을 뿐만 아니라 향숭의 원료로써 활용되고 있다. 특히 목서의 꽃은 식품의약품안전처 식품원료 목록에 등재되어있는 식품원료이다.Meanwhile, woody plant is a woody plant belonging to the plant kingdom, angiosperm phylum, dicotyledon class, Gentian tree, and ash family. It is a temperate southern tree species, medium-sized tree, and weak in cold resistance, so it is abundant in Korea and China. The flower of Moxeo is a bivalent flower that blooms in October-November and has a very fragrant scent. In the southern region of Korea, it is mainly used as a landscaping tree and as a raw material for incense. In particular, the flower of Moxeo is a food ingredient listed on the Ministry of Food and Drug Safety's list of food ingredients.
본 발명은 탈모 예방 또는 치료용 약학 조성물을 제공하는 것을 목적으로 한다.The purpose of the present invention is to provide a pharmaceutical composition for preventing or treating hair loss.
본 발명은 모발 건강 개선용 건강기능식품을 제공하는 것을 목적으로 한다.The purpose of the present invention is to provide a health functional food for improving hair health.
본 발명은 탈모 방지 및 발모 촉진용 화장료 조성물을 제공하는 것을 목적으로 한다.The purpose of the present invention is to provide a cosmetic composition for preventing hair loss and promoting hair growth.
1. 목서 추출물 또는 이의 분획물을 포함하는 탈모 예방 또는 치료용 약학 조성물.1. A pharmaceutical composition for preventing or treating hair loss containing an extract or fraction thereof.
2. 위 1에 있어서, 상기 목서는 목서의 꽃, 줄기, 잎, 열매, 뿌리 또는 이들의 조합인 것인, 탈모 예방 또는 치료용 약학 조성물.2. The pharmaceutical composition for preventing or treating hair loss according to 1 above, wherein the plant is a flower, stem, leaf, fruit, root, or a combination thereof.
3. 위 1에 있어서, 상기 목서 추출물은 물, C1 내지 C6 알코올 또는 이들의 혼합용매로 추출된 것인, 탈모 예방 또는 치료용 약학 조성물.3. The pharmaceutical composition for the prevention or treatment of hair loss according to 1 above, wherein the extract of Moxa extract is extracted with water, C 1 to C 6 alcohol, or a mixed solvent thereof.
4. 위 1에 있어서, 상기 목서 추출물은 에탄올 수용액으로 추출된 것인, 탈모 예방 또는 치료용 약학 조성물. 4. The pharmaceutical composition for the prevention or treatment of hair loss according to 1 above, wherein the extract of Moxus chinensis is extracted with an aqueous ethanol solution.
5. 목서 추출물 또는 이의 분획물을 포함하는 모발 건강 개선용 건강기능식품.5. Health functional food for improving hair health containing extract or fractions thereof.
6. 위 5에 있어서, 상기 목서는 목서의 꽃, 줄기, 잎, 열매, 뿌리 또는 이들의 조합인 것인, 모발 건강 개선용 건강기능식품.6. The health functional food for improving hair health according to item 5 above, wherein the plant is a flower, stem, leaf, fruit, root, or a combination thereof.
7. 위 5에 있어서, 상기 목서 추출물은 물, C1 내지 C6 알코올 또는 이들의 혼합용매로 추출된 것인, 모발 건강 개선용 건강기능식품.7. The health functional food for improving hair health according to item 5 above, wherein the extract is extracted with water, C 1 to C 6 alcohol, or a mixed solvent thereof.
8. 위 5에 있어서, 상기 목서 추출물은 에탄올 수용액으로 추출된 것인, 모발 건강 개선용 건강기능식품.8. The health functional food for improving hair health according to item 5 above, wherein the extract of the woody plant is extracted with an aqueous ethanol solution.
9. 목서 추출물 또는 이의 분획물을 포함하는 탈모 방지 및 발모 촉진용 화장료 조성물.9. A cosmetic composition for preventing hair loss and promoting hair growth, comprising extract or fractions thereof.
10. 위 9에 있어서, 상기 목서는 목서의 꽃, 줄기, 잎, 열매, 뿌리 또는 이들의 조합인 것인, 탈모 방지 및 발모 촉진용 화장료 조성물.10. The cosmetic composition for preventing hair loss and promoting hair growth according to item 9 above, wherein the plant is a flower, stem, leaf, fruit, root, or a combination thereof.
11. 위 9에 있어서, 상기 목서 추출물은 물, C1 내지 C6 알코올 또는 이들의 혼합용매로 추출된 것인, 탈모 방지 및 발모 촉진용 화장료 조성물.11. The cosmetic composition for preventing hair loss and promoting hair growth according to item 9 above, wherein the extract is extracted with water, C 1 to C 6 alcohol, or a mixed solvent thereof.
12. 위 9에 있어서, 상기 목서 추출물은 에탄올 수용액으로 추출된 것인, 탈모 방지 및 발모 촉진용 화장료 조성물.12. The cosmetic composition for preventing hair loss and stimulating hair growth according to item 9 above, wherein the extract of the woody plant is extracted with an aqueous ethanol solution.
13. 위 9에 있어서, 상기 화장료 조성물은 헤어 토닉, 헤어 로션, 헤어 오일, 헤어 샴푸, 헤어 린스, 헤어 컨디셔너, 헤어 트리트먼트, 헤어 크림, 헤어 팩, 헤어 스프레이, 헤어 에센스, 헤어 무스, 헤어 겔 및 비누로 이루어진 군에서 선택된 어느 하나의 제형을 가지는 것인, 탈모 방지 및 발모 촉진용 화장료 조성물.13. The method of item 9 above, wherein the cosmetic composition includes hair tonic, hair lotion, hair oil, hair shampoo, hair rinse, hair conditioner, hair treatment, hair cream, hair pack, hair spray, hair essence, hair mousse, and hair gel. And a cosmetic composition for preventing hair loss and promoting hair growth, having any one formulation selected from the group consisting of soap.
본 발명의 목서 추출물은 두피염증에 의해 진행되는 탈모에 있어 대식세포 및 모유두세포에서 유의적인 항염증 활성을 통하여 탈모를 예방할 수 있고, 모발성장을 촉진할 수 있다.The extract of the present invention can prevent hair loss and promote hair growth through significant anti-inflammatory activity in macrophages and dermal papilla cells in hair loss caused by scalp inflammation.
또한, 본 발명의 목서 추출물은 폐경 여성의 성호르몬 변화에 의한 탈모를 예방하고 모발성장을 촉진시킬 수 있다.In addition, the Moxa extract of the present invention can prevent hair loss caused by changes in sex hormones in menopausal women and promote hair growth.
도 1은 두피를 구성하고 있는 L929 섬유아세포, Raw264.7 대식세포 및 인간 초대배양 모유두세포에서 목서 추출물(OFLE)의 세포독성 분석 결과를 나타낸다.
도 2는 두피를 구성하고 있는 L929 섬유아세포 및 인간 초대배양 모유두세포에서 목서 추출물(OFLE)의 세포생존율 분석 결과를 나타낸다.
도 3은 Raw264.7 대식세포에서 목서 추출물(OFLE)의 염증유도인자 nitric oxide (NO)의 발현 감소를 통한 항염증 효능을 나타낸다.
도 4는 일 구체예에 따른 Raw264.7 대식세포에서 목서 추출물(OFLE)의 염증유도인자 prostaglandin E2 (PGE2)의 발현 감소를 통한 항염증 효능을 나타낸다.
도 5는 Raw264.7 대식세포에서 목서 추출물(OFLE)의 염증유도인자 inducible nitric oxide synthase (iNOS) 및 cyclooxygenase-2 (COX-2) 발현 감소를 통한 항염증 효능을 나타낸다.
도 6은 인간 초대배양 모유두세포에서 목서 추출물(OFLE)의 염증유도인자 inducible nitric oxide synthase (iNOS) 및 cyclooxygenase-2 (COX-2) 발현 감소를 통한 항염증 효능을 나타낸다.
도 7은 인간 초대배양 모유두세포에서 목서 추출물(OFLE)의 대표적 탈모 관련 염증유도인자 prostaglandin D2 (PGD2)의 발현 감소를 통한 항염증 효능을 나타낸다.
도 8은 인간의 폐경 후 발생되는 성호르몬 변화에 따른 탈모 및 모발성장 억제 유사 동물을 제작하기 위하여 실험동물의 난소절제 후 폐경 동물모델에 목서 추출물(OFLE) 5 mg/Kg 및 10 mg/Kg을 4주간 구강투여 후의 모발 성장 효과를 나타낸다.Figure 1 shows the results of cytotoxicity analysis of OFLE extract in L929 fibroblasts, Raw264.7 macrophages, and human primary cultured dermal papilla cells constituting the scalp.
Figure 2 shows the results of cell viability analysis of OFLE extract in L929 fibroblasts and human primary cultured dermal papilla cells constituting the scalp.
Figure 3 shows the anti-inflammatory effect of OFLE extract in Raw264.7 macrophages by reducing the expression of the inflammation-inducing factor nitric oxide (NO).
Figure 4 shows the anti-inflammatory effect of OFLE extract in Raw264.7 macrophages according to one embodiment by reducing the expression of the inflammation-inducing factor prostaglandin E2 (PGE2).
Figure 5 shows the anti-inflammatory effect of OFLE extract in Raw264.7 macrophages by reducing the expression of inflammation-inducing factors inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2).
Figure 6 shows the anti-inflammatory effect of OFLE extract in human primary cultured dermal papilla cells by reducing the expression of inflammation-inducing factors inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2).
Figure 7 shows the anti-inflammatory effect of OFLE extract in human primary cultured dermal papilla cells by reducing the expression of prostaglandin D2 (PGD2), a representative hair loss-related inflammation-inducing factor.
Figure 8 shows 5 mg/Kg and 10 mg/Kg of OFLE extract (OFLE) in a menopausal animal model after ovariectomy of experimental animals to produce animals similar to hair loss and hair growth inhibition due to changes in sex hormones that occur after menopause in humans. Shows the hair growth effect after oral administration for 4 weeks.
본 발명은 목서(Osmanthus fragrans) 추출물에 관한 것이다.The present invention relates to Osmanthus fragrans extract.
본 발명은 목서 추출물 또는 이의 분획물을 포함하는 탈모 예방 또는 치료용 약학 조성물을 제공한다.The present invention provides a pharmaceutical composition for preventing or treating hair loss containing an extract or fraction thereof.
상기 목서 추출물은 목서(Osmanthus fragrans)의 전초 또는 그 일부분, 또는 이들로부터 유래된 재료들이 용매에 의해 추출된 추출물이다. 목서(Osmanthus fragrans) 추출에 이용되는 목서의 부위는 목서의 꽃, 줄기, 잎, 열매, 뿌리 또는 이들의 조합일 수 있다. 예를 들어, 목서의 꽃 및 잎이 추출에 이용될 수 있다.The Osmanthus fragrans extract is an extract obtained by extracting the entire plant of Osmanthus fragrans , its parts, or materials derived from them using a solvent. Osmanthus fragrans The parts of Osmanthus fragrans used for extraction may be its flowers, stems, leaves, fruits, roots, or a combination thereof. For example, the flowers and leaves of the plant can be used for extraction.
본 명세서에서 용어 “탈모 치료(treat)”는 자연 치유에 비하여 단축된 시간에 이뤄지는 발모 또는 모발 성장을 의미할 수 있다. 상기 탈모 치료는 탈모증 개선 및 또는 완화를 포함할 수 있다. 또한 상기 탈모 치료는 탈모와 관련된 질환의 치료 또는 모발 성장 촉진과 관련된 일련의 활동을 모두 포함하는 것일 수 있다.As used herein, the term “hair loss treatment” may refer to hair growth or hair growth that occurs in a shorter time compared to natural healing. The hair loss treatment may include improving and or alleviating alopecia. Additionally, the hair loss treatment may include a series of activities related to the treatment of diseases related to hair loss or the promotion of hair growth.
상기 탈모는 폐경 여성의 성호르몬 변화에 의해 발병한 것일 수 있다.The hair loss may be caused by changes in sex hormones in postmenopausal women.
상기 목서의 추출에 이용되는 용매는 물, 유기용매 또는 이들의 혼합물일 수 있다. 상기 유기용매는 C1 내지 C6 알코올 또는 이들의 혼합물일 수 있고, 예를 들어 메탄올, 에탄올, 프로판올, 이소프로판올, 1,3-프로판디올, 부탄올, 펜탄올, 헥산올 등일 수 있다. 상기 유기용매는 C1 내지 C4 알코올 또는 이들의 혼합물일 수 있다. 또한, 상기 알코올은 주정 알코올일 수 있다.The solvent used for extraction of the above-mentioned substances may be water, organic solvent, or a mixture thereof. The organic solvent may be C 1 to C 6 alcohol or a mixture thereof, for example, methanol, ethanol, propanol, isopropanol, 1,3-propanediol, butanol, pentanol, hexanol, etc. The organic solvent may be C 1 to C 4 alcohol or a mixture thereof. Additionally, the alcohol may be spirit alcohol.
상기 용매는 물과 알코올의 혼합물인 알코올 수용액일 수 있다. 알코올 수용액의 알코올 농도는 1 내지 99.5 (v/v)%, 10 내지 99.5 (v/v)%, 1 내지 90(v/v)%, 5 내지 90(v/v)%, 10 내지 90(v/v)%, 20 내지 90(v/v)%, 30 내지 90(v/v)%, 40 내지 90(v/v)%, 50 내지 90(v/v)%, 60 내지 90(v/v)%, 70 내지 90(v/v)%, 10 내지 80(v/v)%, 20 내지 80(v/v)%, 30 내지 80(v/v)%, 40 내지 80(v/v)%, 50 내지 80(v/v)%, 60 내지 80(v/v)%, 또는 70 내지 80(v/v)% 일 수 있다. 상기 알코올 수용액은 에탄올 수용액일 수 있으며, 예를 들어 70% 에탄올 수용액, 80% 에탄올 수용액 등일 수 있다.The solvent may be an aqueous alcohol solution, which is a mixture of water and alcohol. The alcohol concentration of the aqueous alcohol solution is 1 to 99.5 (v/v)%, 10 to 99.5 (v/v)%, 1 to 90 (v/v)%, 5 to 90 (v/v)%, 10 to 90 ( v/v)%, 20 to 90(v/v)%, 30 to 90(v/v)%, 40 to 90(v/v)%, 50 to 90(v/v)%, 60 to 90( v/v)%, 70 to 90(v/v)%, 10 to 80(v/v)%, 20 to 80(v/v)%, 30 to 80(v/v)%, 40 to 80( v/v)%, 50 to 80(v/v)%, 60 to 80(v/v)%, or 70 to 80(v/v)%. The alcohol aqueous solution may be an ethanol aqueous solution, for example, a 70% ethanol aqueous solution, an 80% ethanol aqueous solution, etc.
상기 추출은 상기 목서 전초, 그 일부분, 또는 이들로부터 유래된 재료에 대하여 상기 추출 용매를 3 내지 10 (부피/중량)배, 예를 들어, 3 내지 7 (부피/중량)배, 3 내지 5 (부피/중량)배, 5 내지 10 (부피/중량)배, 또는 4 내지 10배 첨가하는 것일 수 있다. 예를 들어, 목서 전초, 그 일부분, 또는 이들로부터 유래된 재료 1 kg에 대하여 추출 용매를 3 내지 10 L 첨가하는 것일 수 있으며, 바람직하게는 추출 용매로 에탄올, 메탄올 등의 C1 내지 C4 알코올 또는 C1 내지 C4 알코올 수용액을 사용하는 것일 수 있다. 더욱 바람직하게는 시료로 목서의 꽃과 잎을 이용하여 주정 에탄올 10-80%를 시료의 10배수로 가하여 0-40℃ 범위에서 72시간 동안 추출하는 것일 수 있고, 2회 내지 3회 반복 추출하는 것일 수 있다.The extraction is performed by adding the extraction solvent 3 to 10 (volume/weight) times, for example, 3 to 7 (volume/weight) times, 3 to 5 ( It may be added 5 to 10 times (volume/weight) times, or 4 to 10 times (volume/weight). For example, 3 to 10 L of extraction solvent may be added per 1 kg of woody plant, parts thereof, or materials derived from them, and preferably the extraction solvent is C 1 to C 4 alcohol such as ethanol or methanol. Alternatively, an aqueous C 1 to C 4 alcohol solution may be used. More preferably, the sample may be extracted by using the flowers and leaves of the plant, adding 10-80% distilled ethanol to 10 times the sample size, extracting the extract for 72 hours in the range of 0-40°C, and repeating the extraction 2 to 3 times. You can.
상기 목서 추출물의 추출은 열수 추출, 냉침 추출, 환류 추출, 여과 또는 초음파 추출하는 것일 수 있다. 상세하게는 상기 추출은 가온된 액체 추출, 가압된 액체 추출 (pressurized liquid extraction: PLE), 초음파 도움을 받은 추출 (microwave assisted extraction: MAE), 아임계 추출 (subcritical extraction: SE), 또는 이들의 조합에 의하여 수행될 수 있다. 상기 아임계 추출은 아임계 수추출 (subcritical water extraction: SWE)일 수 있다. 아임계 수추출은 초가열된 수추출 (superheated water extraction) 또는 가압된 열수 추출 (pressurized hot water extraction: PHWE)라고도 한다. 상기 가온된 액체 추출은 환류 추출일 수 있다.Extraction of the wood extract may be hot water extraction, cold needle extraction, reflux extraction, filtration, or ultrasonic extraction. Specifically, the extraction may include warm liquid extraction, pressurized liquid extraction (PLE), microwave assisted extraction (MAE), subcritical extraction (SE), or a combination thereof. It can be performed by . The subcritical extraction may be subcritical water extraction (SWE). Subcritical water extraction is also called superheated water extraction or pressurized hot water extraction (PHWE). The warm liquid extraction may be reflux extraction.
상기 목서 추출물의 추출 온도는 추출 방법에 따라 적절하게 선택될 수 있다. 예를 들어 4℃ 내지 100℃, 4℃ 내지 90℃, 4℃ 내지 80℃, 4℃ 내지 70℃, 4℃ 내지 50℃, 4℃ 내지 40℃, 4℃ 내지 30℃, 10℃ 내지 90℃, 10℃ 내지 80℃, 10℃ 내지 70℃, 10℃ 내지 50℃, 10℃ 내지 40℃, 10℃ 내지 30℃, 20℃ 내지 90℃, 20℃ 내지 80℃, 20℃ 내지 70℃, 20℃ 내지 50℃, 20℃ 내지 40℃ 또는 20℃ 내지 30℃ 등일 수 있다.The extraction temperature of the above extract can be appropriately selected depending on the extraction method. For example 4°C to 100°C, 4°C to 90°C, 4°C to 80°C, 4°C to 70°C, 4°C to 50°C, 4°C to 40°C, 4°C to 30°C, 10°C to 90°C. , 10°C to 80°C, 10°C to 70°C, 10°C to 50°C, 10°C to 40°C, 10°C to 30°C, 20°C to 90°C, 20°C to 80°C, 20°C to 70°C, 20 It may be ℃ to 50℃, 20℃ to 40℃, or 20℃ to 30℃.
상기 목서 추출물의 추출 시간은 추출 방법 및 추출 시간에 따라 적절하게 선택될 수 있다. 예를 들어 1 시간 내지 2개월, 1 시간 내지 1개월, 1 시간 내지 15일, 1 시간 내지 10일, 1 시간 내지 5일, 1 시간 내지 3일, 1 시간 내지 2일, 1 시간 내지 1일, 1 시간 내지 12시간, 1시간 내지 6시간, 1시간 내지 3시간, 5 시간 내지 1개월, 5 시간 내지 15일, 5 시간 내지 10일, 5 시간 내지 5일, 5 시간 내지 3일, 5 시간 내지 2일, 5 시간 내지 1일, 5 시간 내지 12시간, 10 시간 내지 1개월, 10 시 간 내지 15일, 10 시간 내지 10일, 10 시간 내지 5일, 10 시간 내지 3일, 또는 10 시간 내지 2일일 수 있다.The extraction time of the above extract can be appropriately selected depending on the extraction method and extraction time. For example, 1 hour to 2 months, 1 hour to 1 month, 1 hour to 15 days, 1 hour to 10 days, 1 hour to 5 days, 1 hour to 3 days, 1 hour to 2 days, 1 hour to 1 day. , 1 hour to 12 hours, 1 hour to 6 hours, 1 hour to 3 hours, 5 hours to 1 month, 5 hours to 15 days, 5 hours to 10 days, 5 hours to 5 days, 5 hours to 3 days, 5 2 hours to 2 days, 5 hours to 1 day, 5 hours to 12 hours, 10 hours to 1 month, 10 hours to 15 days, 10 hours to 10 days, 10 hours to 5 days, 10 hours to 3 days, or 10 hours It can be anywhere from an hour to two days.
상기 추출은 식물체 잔사 및 추출액을 여과 등의 알려진 방법에 의하여 분리된 것일 수 있다.The extraction may be performed by separating plant residues and extracts using known methods such as filtration.
상기 추출은 또한 얻어 진 추출액으로부터 감압 농축과 같은 알려진 방법에 의하여 용매를 제거하는 것을 포함할 수 있다.The extraction may also include removing the solvent from the obtained extract by known methods such as concentration under reduced pressure.
상기 추출은 또한 얻어진 추출물을 동결건조와 같은 건조에 의하여 건조 추출물을 제조하는 것을 포함할 수 있다.The extraction may also include preparing a dry extract by drying the obtained extract, such as freeze-drying.
본 명세서에서 용어 "분획물"은 여러 다양한 구성 성분들을 포함하는 혼합물(예를 들어 목서 추출물)로부터 특정 성분 또는 특정 성분 그룹을 분리하기 위하여 분획을 수행하여 얻어진 결과물을 의미한다.As used herein, the term “fraction” refers to the result obtained by performing fractionation to separate a specific component or specific group of components from a mixture (e.g., Extract of the Extract) containing various components.
상기 분획물을 얻는 데에 사용되는 분획 용매의 종류는 특별히 제한되지 아니하며, 당해 기술 분야에서 공지된 임의의 용매를 사용할 수 있다. 예를 들어 물, 증류수, 알코올 등의 극성용매; 헥산, 에틸아세테이트, 클로로포름, 디클로로메탄 등의 비극성용매 등을 이용할 수 있다. 이들은 단독으로 사용되거나 2종 이상 혼합하여 사용될 수 있다.The type of fractionation solvent used to obtain the fraction is not particularly limited, and any solvent known in the art can be used. For example, polar solvents such as water, distilled water, and alcohol; Non-polar solvents such as hexane, ethyl acetate, chloroform, and dichloromethane can be used. These may be used alone or in combination of two or more types.
상기 목서 추출물은 섬유아세포, 대식세포 및 모유두세포에서 특이적 세포독성이 없는 우수한 생물학적 안전성을 갖는다.The extract has excellent biological safety with no specific cytotoxicity in fibroblasts, macrophages and dermal papilla cells.
특정 이론에 제한됨이 없이, 탈모증은 두피 및 이를 구성하고 있는 조직을 포함한 섬유아세포, 대식세포 및 모유두 세포에서 염증으로 인해 발생하는 것일 수 있다.Without being limited to a particular theory, alopecia may be caused by inflammation in fibroblasts, macrophages, and dermal papilla cells, including the scalp and the tissues that compose it.
상기 목서 추출물은 두피 열의 원인인 과도한 피지 분출로 모낭 속에 박테리아 서식으로 인한 두피 염증과 관련하여 대식세포에서 유의적인 항염증 활성을 갖는다.The extract has significant anti-inflammatory activity in macrophages in relation to scalp inflammation caused by bacteria colonizing hair follicles due to excessive sebum exudation, which is the cause of scalp heat.
상기 목서 추출물은 모유두세포에서 유의적인 항염증 활성을 통하여 모낭 내 염증으로 기인된 모발성장 억제를 완화시키는 활성을 갖는다.The extract has the activity of alleviating hair growth inhibition caused by inflammation within hair follicles through significant anti-inflammatory activity in dermal papilla cells.
예를 들어 상기 목서 추출물은 대식세포 및 모유두세포에서 염증관련 바이오마커인 inducible nitric oxide synthase, nitric oxide(NO), cyclooxygenase-2(COX-2) 및 prostaglandin E2(PGE2)을 억제할 수 있으며, 탈모와 관련된 밀접한 염증유도 인자인 prostaglandin D2(PGD2) 및 염증성 사이토카인의 발현을 억제할 수 있다.For example, the above extract can inhibit the inflammation-related biomarkers inducible nitric oxide synthase, nitric oxide (NO), cyclooxygenase-2 (COX-2), and prostaglandin E2 (PGE2) in macrophages and dermal papilla cells, and can prevent hair loss. It can suppress the expression of prostaglandin D2 (PGD2), a closely related inflammation-inducing factor, and inflammatory cytokines.
상기 목서 추출물은 여성의 폐경으로 인한 성호르몬 변화로 기인된 탈모 및 모발 성장 감소에서 유의적인 모발성장을 촉진하는 활성을 갖는다.The extract has the activity of significantly promoting hair growth in hair loss and hair growth reduction caused by changes in sex hormones due to menopause in women.
본 발명의 약학 조성물은 조성물 총 중량에 대하여 0.001 중량% 내지 99 중량%, 0.001 중량% 내지 80 중량%, 0.01 중량% 내지 60 중량%, 0.01 중량% 내지 40 중량%, 0.01 중량% 내지 30 중량%, 0.01 중량% 내지 20 중량%, 0.01 중량% 내지 10 중량%, 0.01 중량% 내지 5 중량%, 0.05 중량% 내지 60 중량%, 0.05 중량% 내지 40 중량%, 0.05 중량% 내지 30 중량%, 0.05 중량% 내지 20 중량%, 0.05 중량% 내지 10 중량%, 0.05 중량% 내지 5 중량%, 0.1 중량% 내지 60 중량%, 0.1 중량% 내지 40 중량%, 0.1 중량% 내지 30 중량%, 0.1 중량% 내지 20 중량%, 0.1 중량% 내지 10 중량%, 또는 0.1 중량% 내지 5 중량%의 목서 추출물을 포함할 수 있다.The pharmaceutical composition of the present invention is 0.001% to 99% by weight, 0.001% to 80% by weight, 0.01% to 60% by weight, 0.01% to 40% by weight, 0.01% to 30% by weight based on the total weight of the composition. , 0.01% to 20% by weight, 0.01% to 10% by weight, 0.01% to 5% by weight, 0.05% to 60% by weight, 0.05% to 40% by weight, 0.05% to 30% by weight, 0.05% by weight. Weight % to 20 weight %, 0.05 weight % to 10 weight %, 0.05 weight % to 5 weight %, 0.1 weight % to 60 weight %, 0.1 weight % to 40 weight %, 0.1 weight % to 30 weight %, 0.1 weight % It may include from 20% to 20% by weight, from 0.1% to 10% by weight, or from 0.1% to 5% by weight of a woody extract.
본 발명의 약학 조성물은 경구 또는 비경구 투여될 수 있고, 비경구 투여에는 예를 들어 정맥내 투여, 피하 투여, 근육 투여, 복강 투여, 내피 투여, 국소 투여, 비강내 투여, 폐내 투여, 피부도포 등이 있으며, 바람직하게는 경구 투여되는 것일 수 있다.The pharmaceutical composition of the present invention can be administered orally or parenterally, and parenteral administration includes, for example, intravenous administration, subcutaneous administration, intramuscular administration, intraperitoneal administration, endothelial administration, topical administration, intranasal administration, intrapulmonary administration, and dermal application. etc., and may preferably be administered orally.
상기 투여는 임의의 수단에 의하여 대상에 직접적으로 투여될 수 있다. 상기 투여는 전신적으로 또는 국부적으로 투여될 수 있다.The administration may be administered directly to the subject by any means. The administration may be administered systemically or locally.
상기 투여 대상은 포유동물일 수 있으며, 예를 들어 사람, 소, 말, 돼지, 개, 양, 염소 또는 고양이 등일 수 있다.The administration subject may be a mammal, for example, a human, cow, horse, pig, dog, sheep, goat, or cat.
상기 투여는 목서 추출물을 개체의 체중에 따라 적절하게 투여하는 것일 수 있으며, 예를 들어 0.1 mg 내지 1,000 mg, 예를 들어, 0.1 mg 내지 500 mg, 0.1 mg 내지 100 mg, 0.1 mg 내지 50 mg, 0.1 mg 내지 25 mg, 1 mg 내지 1,000 mg, 1 mg 내지 500 mg, 1 mg 내지 100 mg, 1 mg 내지 50 mg, 1 mg 내지 25 mg, 5mg 내지 1,000 mg, 5 mg 내지 500 mg, 5 mg 내지 100 mg, 5 mg 내지 50 mg, 5 mg 내지 25 mg, 10mg 내지 1,000 mg, 10 mg 내지 500 mg, 10 mg 내지 100 mg, 10 mg 내지 50 mg, 또는 10 mg 내지 25 mg을 투여하는 것일 수 있다.The administration may be to appropriately administer the Extract of the Extract according to the body weight of the individual, for example, 0.1 mg to 1,000 mg, for example, 0.1 mg to 500 mg, 0.1 mg to 100 mg, 0.1 mg to 50 mg, 0.1 mg to 25 mg, 1 mg to 1,000 mg, 1 mg to 500 mg, 1 mg to 100 mg, 1 mg to 50 mg, 1 mg to 25 mg, 5 mg to 1,000 mg, 5 mg to 500 mg, 5 mg to It may be administered at 100 mg, 5 mg to 50 mg, 5 mg to 25 mg, 10 mg to 1,000 mg, 10 mg to 500 mg, 10 mg to 100 mg, 10 mg to 50 mg, or 10 mg to 25 mg. .
본 발명의 약학적 조성물은 고체 또는 액제 제형의 형태로 제형화될 수 있다. 고체 제형은 예를 들어, 정제, 캡슐제(연질 & 경질 캡슐제), 산제, 과립제, 환제, 트로키제 등일 수 있으며, 액체 제형은 예를 들어, 엘릭서, 현탁액제, 유액제, 용액제, 시럽제, 리모나아데제 등의 형태일 수 있다. 정제의 경우, 활성 성분 이외에도, 락토스, 옥수수 전분 등과 같은 담체, 마그네슘 스테아레이트 등과 같은 활택제, 메틸셀룰로오스, 미결정 셀룰로오스, 폴리비닐알코올 등과 같은 결합제, 벤토나이트, 알긴산나트륨 등과 같은 붕해제 등이 통상적으로 추가될 수 있다. 액제의 경우, 활성 성분을 정제수, 생리식염수 등과 같은 담체, 및 필요에 따라 모노스테아린산수크로스 등과 같은 용해보조제, 폴리비닐피롤리돈 등과 같은 안정화제 등과 함께 제제화할 수 있으며, 경구용 수성 현탁액제의 경우, 활성 성분을 현탁화제, 및 필요에 따라 계면활성제, 보존제, 안정화제 등과 함께 제제화할 수 있다.The pharmaceutical composition of the present invention may be formulated in the form of a solid or liquid formulation. Solid dosage forms may be, for example, tablets, capsules (soft & hard capsules), powders, granules, pills, troches, etc., and liquid dosage forms may be, for example, elixirs, suspensions, emulsions, solutions, syrups, etc. , rimonadese, etc. In the case of tablets, in addition to the active ingredients, carriers such as lactose, corn starch, etc., lubricants such as magnesium stearate, binders such as methylcellulose, microcrystalline cellulose, polyvinyl alcohol, etc., and disintegrants such as bentonite and sodium alginate are usually added. It can be. In the case of a liquid formulation, the active ingredient can be formulated with a carrier such as purified water, physiological saline, etc., and, if necessary, a solubilizing agent such as sucrose monostearate, and a stabilizer such as polyvinylpyrrolidone. In this case, the active ingredient can be formulated with a suspending agent and, if necessary, a surfactant, preservative, stabilizer, etc.
본 발명의 약학적 조성물의 투여량은 투여방법, 복용자의 연령, 성별, 환자의 중증도, 상태, 불활성율, 및 병용되는 약물을 고려하여 결정할 수 있으며, 1회 또는 수회로 나누어 투여할 수 있다.The dosage of the pharmaceutical composition of the present invention can be determined considering the administration method, the age and gender of the recipient, the patient's severity, condition, inactivation rate, and concomitant drugs, and can be administered once or in divided doses.
본 발명은 목서 추출물 또는 이의 분획물을 포함하는 모발 건강 개선용 건강기능식품을 제공한다.The present invention provides a health functional food for improving hair health containing an extract or a fraction thereof.
상기 목서 추출물은 전술한 바와 같다. 예를 들어 목서 추출에 이용되는 목서의 부위, 목서 추출에 이용되는 용매, 추출 방법, 추출 온도, 및 추출 시간 등의 범위는 "목서 추출물 또는 이의 분획물을 포함하는 탈모 예방 또는 치료용 약학 조성물"에서 기술한 것과 같다.The wood extract extract was as described above. For example, the range of the part of the tree used for extracting the tree, solvent used for extracting the tree, extraction method, extraction temperature, and extraction time is in "Pharmaceutical composition for preventing or treating hair loss comprising extract of the tree or a fraction thereof." Same as described.
상기 목서 추출물 또는 이의 분획물은 대식세포 및 모유두세포에 항염증 활성을 나타냄으로써, 모발 건강을 개선시킬 수 있으며, 상기 모발 건강 개선은 모발 밀도, 탄력 및 윤기 등의 모발 건강상태의 유지 및 개선을 포함한다.The extract or fraction thereof can improve hair health by exhibiting anti-inflammatory activity on macrophages and dermal papilla cells, and the hair health improvement includes maintaining and improving hair health conditions such as hair density, elasticity, and shine. do.
본 발명의 건강기능식품은 상기 구절초 추출물 또는 그 과립 이외에 통상의 식품 첨가물을 포함할 수 있으며, 식품 첨가물로서의 적합 여부는 다른 규정이 없는 한, 식품의약품안전처에 승인된 식품 첨가물 공전의 총칙 및 일반 시험법 등에 따라 해당 품목에 관한 규격 및 기준에 의하여 판정한다.The health functional food of the present invention may contain common food additives in addition to the above-mentioned Gujeolcho extract or its granules, and its suitability as a food additive is determined by the general provisions and general provisions of the food additive code approved by the Ministry of Food and Drug Safety, unless otherwise specified. It is determined according to the specifications and standards for the relevant item according to the test method, etc.
식품 첨가물 공전에 수재된 품목으로는 예를 들어, 케톤류, 글리신, 구연산칼슘, 니코틴산, 계피산 등의 화학적 합성물; 감색소, 감초추출물, 결정셀룰로오스, 고량색소, 구아검 등의 천연첨가물; L-글루타민산나트륨 제제, 면류 첨가알칼리제, 보존료제제, 타르색소제제 등의 혼합제제류 등을 포함하나, 이에 제한되지 않는다.Items listed in the Food Additives Code include, for example, chemical compounds such as ketones, glycine, calcium citrate, nicotinic acid, and cinnamic acid; Natural additives such as dark pigment, licorice extract, crystalline cellulose, high-quality pigment, and guar gum; It includes, but is not limited to, mixed preparations such as L-glutamate sodium preparations, noodle added alkaline preparations, preservative preparations, and tar coloring preparations.
정제 형태의 건강기능식품은 상기 추출물을 부형제, 결합제, 붕해제 및 다른 첨가제와 혼합한 혼합물을 통상의 방법으로 과립화한 다음, 활택제 등을 넣어 압축 성형하거나, 상기 혼합물을 직접 압축 성형할 수 있다. 또한 상기 정제 형태의 건강기능식품은 필요에 따라 교미제 등을 함유할 수도 있다.Health functional foods in the form of tablets can be made by granulating a mixture of the extract with excipients, binders, disintegrants and other additives in a conventional manner, then adding a lubricant and compression molding, or compression molding the mixture directly. there is. In addition, the health functional food in the form of tablets may contain flavoring agents, etc., if necessary.
캅셀 형태의 건강기능식품 중 경질 캅셀제는 통상의 경질 캅셀에 상기 추출물을 부형제 등의 첨가제와 혼합한 혼합물을 충진하여 제조할 수 있으며, 연질 캅셀제는 상기 추출물을 부형제 등의 첨가제와 혼합한 혼합물을 젤라틴과 같은 캅셀기제에 충진하여 제조할 수 있다. 상기 연질 캅셀제는 필요에 따라 글리세린 또는 소르비톨 등의 가소제, 착색제, 보존제 등을 함유할 수 있다.Among capsule-type health functional foods, hard capsules can be manufactured by filling a regular hard capsule with a mixture of the extract and additives such as excipients, and soft capsules can be manufactured by filling a mixture of the extract with additives such as excipients into gelatin. It can be manufactured by filling a capsule base such as. The soft capsule may contain plasticizers such as glycerin or sorbitol, colorants, preservatives, etc., if necessary.
환 형태의 건강기능식품은 상기 추출물과 부형제, 결합제, 붕해제 등을 혼합한 혼합물을 기존에 공지된 방법으로 성형하여 조제할 수 있으며, 필요에 따라 백당이나 다른 제피제로 제피할 수 있으며, 또는 전분, 탈크와 같은 물질로 표면을 코팅할 수도 있다.The health functional food in the form of a pill can be prepared by molding a mixture of the above extract with excipients, binders, disintegrants, etc., using a known method. If necessary, it can be coated with white sugar or another coating agent, or starch. , the surface can also be coated with a substance such as talc.
과립 형태의 건강기능식품은 상기 추출물과 부형제, 결합제, 붕해제 등을 혼합한 혼합물을 기존에 공지된 방법으로 입상으로 제조할 수 있으며, 필요에 따라 착향제, 교미제 등을 함유할 수 있다.Health functional foods in the form of granules can be prepared by mixing the extract with excipients, binders, disintegrants, etc. into granules using a known method, and may contain flavoring agents, flavoring agents, etc. as needed.
건강기능식품은 음료류, 육류, 초코렛, 식품류, 과자류. 피자, 라면, 기타 면류, 껌류, 사탕류, 아이스크림류, 알코올 음료류, 비타민 복함제 및 건강보조식품류 등일 수 있다.Health functional foods include beverages, meat, chocolate, foods, and confectionery. These may include pizza, ramen, other noodles, gum, candy, ice cream, alcoholic beverages, vitamin supplements, and health supplements.
건강기능식품은 영양제의 용도로 경구 적용될 수 있으며, 적용 형태는 특별히 제한되지 않는다.Health functional foods can be applied orally as nutritional supplements, and the form of application is not particularly limited.
본 발명은 목서 추출물 또는 이의 분획물을 포함하는 탈모 방지 및 발모 촉진용 화장료 조성물을 제공한다.The present invention provides a cosmetic composition for preventing hair loss and promoting hair growth, comprising an extract or a fraction thereof.
상기 목서 추출물 또는 이의 분획물은 전술한 바와 같다. 예를 들어 목서 추출에 이용되는 목서의 부위, 목서 추출에 이용되는 용매, 추출 방법, 추출 온도, 및 추출 시간 등의 범위는 "목서 추출물 또는 이의 분획물을 포함하는 탈모 예방 또는 치료용 약학 조성물"에서 기술한 것과 같다.The extract or fraction thereof is as described above. For example, the range of the part of the tree used for extracting the tree, solvent used for extracting the tree, extraction method, extraction temperature, and extraction time is in "Pharmaceutical composition for preventing or treating hair loss comprising extract of the tree or a fraction thereof." Same as described.
상기 목서 추출물은 대식세포 및 모유두세포에서 유의적인 항염증 활성을 나타냄으로써, 탈모를 방지할 수 있다. 또한, 상기 목서 추출물은 발모를 촉진할 수 있다. The extract can prevent hair loss by exhibiting significant anti-inflammatory activity in macrophages and dermal papilla cells. In addition, the extract from the plant can promote hair growth.
본 발명의 화장료 조성물에는 목서 추출물과 더불어 필요에 따라 통상 화장료에 배합되는 다른 성분을 배합해도 될 수 있다. 이외에 첨가해도 되는 배합 성분으로서는 구체적으로 유지 성분, 보습제, 에몰리엔트제, 계면활성제, 유기 및 무기 안료, 유기 분체, 자외선 흡수제, 방부제, 살균제, 산화 방지제, 추출물, pH 조정제, 알콜, 색소, 향료, 혈행 촉진제, 냉감제, 제한(制汗)제, 정제수 등을 들 수 있다.The cosmetic composition of the present invention may contain other ingredients that are usually added to cosmetics, if necessary, in addition to the Extract of the Extract. Other ingredients that may be added include oils and fats, moisturizers, emollients, surfactants, organic and inorganic pigments, organic powders, ultraviolet absorbers, preservatives, disinfectants, antioxidants, extracts, pH adjusters, alcohol, colorants, and fragrances. , blood circulation promoters, cooling agents, antiperspirants, purified water, etc.
본 발명의 화장료 조성물은 헤어 토닉, 헤어 로션, 헤어 오일, 헤어 샴푸, 헤어 린스, 헤어 컨디셔너, 헤어 트리트먼트, 헤어 크림, 헤어 팩, 헤어 스프레이, 헤어 에센스, 헤어 무스, 헤어 겔 또는 비누 등의 제형을 가지는 것일 수 있다.The cosmetic composition of the present invention can be used in formulations such as hair tonic, hair lotion, hair oil, hair shampoo, hair rinse, hair conditioner, hair treatment, hair cream, hair pack, hair spray, hair essence, hair mousse, hair gel, or soap. It may be possible to have a .
본 발명의 화장료 조성물의 제형이 크림 또는 겔인 경우에는 담체 성분으로서 동물섬유, 식물섬유, 왁스, 파라핀, 전분, 트라가칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등을 포함할 수 있다.When the formulation of the cosmetic composition of the present invention is a cream or gel, animal fiber, plant fiber, wax, paraffin, starch, tragacanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, or zinc oxide are used as carrier ingredients. It can be included.
본 발명의 화장료 조성물의 제형이 용액 또는 유탁액의 경우에는 담체 성분으로서 용매, 용매화제 또는 유탁화제가 이용되고, 예를 들어 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌 글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르를 포함할 수 있다.When the formulation of the cosmetic composition of the present invention is a solution or emulsion, a solvent, solvating agent, or emulsifying agent is used as a carrier component, for example, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, and benzyl benzoate. , propylene glycol, 1,3-butyl glycol oil, glycerol fatty ester, polyethylene glycol, or fatty acid ester of sorbitan.
본 발명의 화장료 조성물의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라가칸트를 포함할 수 있다.When the formulation of the cosmetic composition of the present invention is a suspension, the carrier component includes water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester, and polyoxyethylene sorbitan ester, It may include microcrystalline cellulose, aluminum metahydroxide, bentonite, agar or tragacanth.
본 발명의 화장료 조성물의 제형이 계면-활성제를 함유하는 경우 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코 시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성 유, 리놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등을 포함할 수 있다.When the formulation of the cosmetic composition of the present invention contains a surfactant, the carrier component may include aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyl taurate, sarcosinate, It may include fatty acid amide ether sulfate, alkylamidobetaine, fatty alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, linoline derivative, or ethoxylated glycerol fatty acid ester.
이하, 실시예를 통해 본 발명을 보다 상세하게 설명한다. Hereinafter, the present invention will be described in more detail through examples.
실시예 1. 목서 추출물의 제조Example 1. Preparation of Moxa Extract
목서 잎을 수집하여 평량한 후 10 배 부피의 식품원료로 추출가능 용매인 80% 주정 알코올을 가하였다. 이후 72시간 동안 상온에서 1차 추출하여 상등액을 회수시킨 후 다시 10 배의 80% 주정알코올에 1주간 상온에서 2 및 3차 추출하여 상등액을 회수하였다. 이후 회수된 상등액을 40℃로 조절된 증류장치에서 에탄올을 회수시킨 후 최초상등액의 약 1/5 부피의 조추출물을 회수하였다. 회수된 조추출물을 -80℃로 조절된 초저온냉동고에서 동결시킨 후 동결건조장치에서 동결건조를 실시하여 최초 목서 잎 무게의 약 8.8%의 건조된 추출물을 회수하였다.After the leaves were collected and weighed, 80% distilled alcohol, an extractable solvent, was added to 10 times the volume of food ingredients. Afterwards, the supernatant was recovered by first extraction at room temperature for 72 hours, and then extracted again with 10 times 80% distilled alcohol at room temperature for one week for the second and third extractions to recover the supernatant. Afterwards, ethanol was recovered from the recovered supernatant in a distillation device adjusted to 40°C, and then a crude extract of about 1/5 volume of the initial supernatant was recovered. The recovered crude extract was frozen in an ultra-low temperature freezer adjusted to -80°C and then lyophilized in a freeze-drying device to recover a dried extract of about 8.8% of the initial weight of the Moxa leaf.
실시예 2. 목서 추출물의 세포독성 분석Example 2. Cytotoxicity analysis of woody extract
L929 섬유아세포, Raw264.7 대식세포, 인간 초대배양 모유두세포를 각각 48-well cell culture plate에 각각 1 X 104 cells/well의 농도로 10% FBS와 1% Penicillin/Streptomycin이 포함된 MEM, DMEM, HFDPC Growth Media를 사용하여 배양하였으며, 단층 배양 후 목서 추출물을 농도의존적으로 처리하여 24시간 배양 후 WST 용액을 배지의 10% 양을 처리하고 5% CO2, 37 ℃ 조건에서 2시간 배양하여 흡광도 450nm에서 분광 광도계를 이용하여 세포생존율 측정을 측정하였다. 도 1에 나타낸 바와 같이 목서 추출물(osmanthus fragrans leaf ethanol extracts, OFLE)의 유의적인 생물학적 안전성을 확인하였다.L929 fibroblasts, Raw264.7 macrophages, and human primary cultured dermal papilla cells were cultured in MEM and DMEM containing 10% FBS and 1% Penicillin/Streptomycin at a concentration of 1 , was cultured using HFDPC Growth Media, and after monolayer culture, the woody extract was treated in a concentration-dependent manner. After culturing for 24 hours, 10% of the medium was treated with WST solution and cultured for 2 hours at 5% CO2 and 37°C to obtain an absorbance of 450nm. Cell viability was measured using a spectrophotometer. As shown in Figure 1, significant biological safety of osmanthus fragrans leaf ethanol extracts (OFLE) was confirmed.
실시예 3. 목서 추출물의 세포생존율 분석Example 3. Analysis of cell viability of woody extract
L929 정상세포 및 인간 모유두세포를 각각 1 X 104 cells/well의 농도로 10% FBS와 1% Penicillin/Streptomycin이 포함된 MEM, HFDPC Growth Media를 사용하여 분주하여 배양하였으며, 단층배양 후 목서 추출물을 농도의존적으로 투여한 후 24시간 배양한 뒤 Cell Live/Dead assay를 수행하여 세포생존능 분석을 수행하였다. 살아있는 세포의 세포질에 존재하는 esterase에 의해 분해된 후 녹색의 형광을 나타내는 green calcein AM과 세포사멸로 인한 세포막 결손이 DNA와 결합하여 세포핵을 적색 형광으로 염색시키는 ethidium homodimer-1을 사용하여 분석하였다. 도 2에 나타낸 바와 같이 대조군과 비교하여 사멸세포 수에 변화가 없는 유의적인 세포생존율을 확인하였다.L929 normal cells and human dermal papilla cells were cultured at a concentration of 1 After administration in a concentration-dependent manner, the cells were cultured for 24 hours and then Cell Live/Dead assay was performed to analyze cell viability. Green calcein AM, which shows green fluorescence after being decomposed by esterase present in the cytoplasm of living cells, and ethidium homodimer-1, which binds to DNA and stains the cell nucleus with red fluorescence for cell membrane defects due to apoptosis, were analyzed. As shown in Figure 2, significant cell survival rate was confirmed with no change in the number of dead cells compared to the control group.
실시예 4. Raw264.7 대식세포에서 목서 추출물의 염증유도인자 nitric oxide (NO)의 발현 감소를 통한 항염증 효능Example 4. Anti-inflammatory efficacy of woody extract from Raw264.7 macrophages by reducing the expression of nitric oxide (NO), an inflammation-inducing factor.
목서 잎 추출물에 대한 항염증 효능 분석을 위하여 Raw264.7 대식세포를 12-well cell culture plate에 5 X 106 cells/well의 농도로, 10% FBS와 1% Penicillin/Streptomycin이 포함된 DMEM을 사용하여 배양하였으며, 24 시간 동안 목서 추출물 및 염증유도 물질 LPS(Lipopolysaccharide)를 처리한 후 배양액 내 NO를 Griess reagent를 이용하여 분광광도계 540 nm에서 측정하였다. 도 3에 나타낸 바와 같이 대식세포에서 염증유도 물질 LPS에 의해 증가된 nitric oixde (NO)의 합성을 유의적으로 억제시키는 목서 추출물의 항염증 효과를 확인하였다.In order to analyze the anti-inflammatory efficacy of the extract of the leaf extract, Raw264.7 macrophages were placed in a 12-well cell culture plate at a concentration of 5 The cells were cultured, and after treatment with L. vulgaris extract and the inflammation-inducing substance LPS (Lipopolysaccharide) for 24 hours, NO in the culture medium was measured at 540 nm in a spectrophotometer using a Griess reagent. As shown in Figure 3, the anti-inflammatory effect of the woody extract was confirmed to significantly inhibit the synthesis of nitric acid (NO) increased by the inflammation-inducing substance LPS in macrophages.
실시예 5. Raw264.7 대식세포에서 목서 추출물의 염증유도인자 inducible nitric oxide synthase (iNOS) 및 cyclooxygenase-2 (COX-2) 발현 감소를 통한 항염증 효능Example 5. Anti-inflammatory efficacy of woody extract from Raw264.7 macrophages by reducing the expression of inflammation-inducing factors inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2)
목서 추출물에 대한 항염증 효능 분석을 위하여 Raw264.7 대식세포을 12-well cell culture plate에 5 X106 cells/well의 농도로, 10% FBS와 1% Penicillin/Streptomycin이 포함된 DMEM을 사용하여 배양하였으며, 48 시간 동안 목서 추출물 및 염증유도 물질 LPS를 처리한 후 배양액 내 PGE2를 PGE2 assay kit를 이용하여 분광광도계 450 nm에서 측정하였다. 도 4에 나타낸 바와 같이 대식세포에서 염증유도 물질 LPS에 의해 증가된 PGE2의 합성을 유의적으로 억제시키는 목서 추출물의 항염증 효과를 확인하였다.To analyze the anti-inflammatory efficacy of the Extract of the Extract, Raw264.7 macrophages were cultured in a 12-well cell culture plate at a concentration of 5 , After treatment with L. vulgaris extract and the inflammation-inducing substance LPS for 48 hours, PGE2 in the culture medium was measured at 450 nm in a spectrophotometer using a PGE2 assay kit. As shown in Figure 4, the anti-inflammatory effect of the L. vulgaris extract was confirmed to significantly inhibit the synthesis of PGE2, which was increased by the inflammation-inducing substance LPS, in macrophages.
실시예 6. Raw264.7 대식세포에서 목서 추출물의 염증유도인자 inducible nitric oxide synthase (iNOS) 및 cyclooxygenase-2 (COX-2) 발현 감소를 통한 항염증 효능Example 6. Anti-inflammatory efficacy of woody extract from Raw264.7 macrophages by reducing the expression of inflammation-inducing factors inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2)
목서 추출물에 대한 항염증 효능 분석을 위하여 Raw264.7 대식세포을 12-well cell culture plate에 5 X106 cells/well의 농도로, 10% FBS와 1% Penicillin/Streptomycin이 포함된 DMEM을 사용하여 배양하였으며, 48 시간 동안 목서 추출물 및 염증유도 물질 LPS를 처리한 후 iNOS 및 COX-2 특이적 항체를 이용하여 단백질 발현변화를 western blot을 이용하여 분석하였다. 도 5에 나타낸 바와 같이 대식세포에서 염증유도물질 LPS에 의해 증가된 iNOS 및 COX-2의 발현을 유의적으로 억제시키는 목서 추출물의 항염증 효과를 확인하였다.To analyze the anti-inflammatory efficacy of the Extract of the Extract, Raw264.7 macrophages were cultured in a 12-well cell culture plate at a concentration of 5 , After treatment with woody extract and the inflammation-inducing substance LPS for 48 hours, protein expression changes were analyzed using western blot using iNOS and COX-2 specific antibodies. As shown in Figure 5, the anti-inflammatory effect of the woody extract was confirmed to significantly inhibit the expression of iNOS and COX-2, which were increased by the inflammation-inducing substance LPS, in macrophages.
실시예 7. 인간 초대배양 모유두세포에서 목서 추출물의 염증유도인자 inducible nitric oxide synthase (iNOS) 및 cyclooxygenase-2 (COX-2) 발현 감소를 통한 항염증 효능Example 7. Anti-inflammatory efficacy through reduction of expression of inflammation-inducing factors, inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2), of the extract from Human Primary Cultured Dermal Papilla Cells
목서 추출물에 대한 항염증 효능 분석을 위하여 인간초대배양모유두세포를 12-well cell culture plate에 5 X 106 cells/well의 농도로, 10% FBS와 1% Penicillin/Streptomycin이 포함된 HFDPC Growth Media를 사용하여 배양하였으며, 48 시간 동안 목서 추출물 및 염증유도 물질 LPS를 처리한 후 iNOS 및 COX-2 특이적 항체를 이용하여 단백질 발현변화를 western blot을 이용하여 분석하였다. 도 6에 나타낸 바와 같이 인간초대배양모유두세포에서 염증유도 물질 LPS에 의해 증가된 iNOS 및 COX-2의 발현을 유의적으로 억제시키는 목서 추출물의 항염증 효과를 확인하였다.In order to analyze the anti-inflammatory efficacy of the Extract of the Extract, human primary cultured hair papilla cells were cultured in a 12-well cell culture plate at a concentration of 5 After treatment with LPS extract and the inflammation-inducing substance LPS for 48 hours, protein expression changes were analyzed using western blot using iNOS and COX-2 specific antibodies. As shown in Figure 6, the anti-inflammatory effect of the woody extract significantly inhibited the expression of iNOS and COX-2 increased by the inflammation-inducing substance LPS in human primary cultured hair papilla cells.
실시예 8. 인간초대배양모유두세포에서 목서 추출물의 대표적 탈모 관련 염증유도인자 prostaglandin D2(PGD2)의 발현 감소를 통한 항염증 효능Example 8. Anti-inflammatory efficacy through reduction of expression of prostaglandin D2 (PGD2), a representative hair loss-related inflammation-inducing factor, of P. phyllis extract in human primary cultured hair papilla cells.
목서 추출물에 대한 항염증 효능 분석을 위하여 인간초대배양모유두세포를 12-well cell culture plate에 5 X 106 cells/well의 농도로, 10% FBS와 1% Penicillin/Streptomycin이 포함된 HFDPC Growth Media를 사용하여 배양하였으며, 48 시간 동안 목서 추출물 및 염증유도 물질 LPS를 처리한 후 배양액 내 PGD2를 PGD2 assay kit를 이용하여 분광광도계 450 nm에서 측정하였다. 도 7에 나타낸 바와 같이 인간초대배양모유두세포에서 염증유도 물질 LPS에 의해 증가된 대표적인 탈모 유도관련 병리인자인 PGD2의 합성을 유의적으로 억제시키는 목서 추출물의 항염증 효과를 확인하였다.In order to analyze the anti-inflammatory efficacy of the Extract of the Extract, human primary cultured hair papilla cells were cultured in a 12-well cell culture plate at a concentration of 5 After treatment with the L. vulgaris extract and the inflammation-inducing substance LPS for 48 hours, PGD2 in the culture medium was measured at 450 nm in a spectrophotometer using a PGD2 assay kit. As shown in FIG. 7, the anti-inflammatory effect of the Moxa extract was confirmed to significantly inhibit the synthesis of PGD2, a representative hair loss induction-related pathological factor increased by the inflammation-inducing substance LPS, in human primary cultured hair papilla cells.
실시예 9. 인간의 폐경 후 발생되는 성호르몬 변화에 따른 탈모 및 모발성장 억제 유사 동물을 제작하기 위하여 실험동물의 난소절제 후 폐경 동물모델에 목서 추출물의 탈모 및 모발성장 효과Example 9. Hair loss and hair growth effects of woody extract on a menopausal animal model after ovariectomy of experimental animals to produce animals similar to the inhibition of hair loss and hair growth due to changes in sex hormones that occur after menopause in humans.
인간의 폐경 후 발생되는 성호르몬 변화에 따른 탈모 및 모발성장 억제 유사 동물을 제작하기 위하여 실험동물의 난소절제 후 폐경 동물모델에 목서 추출물 5 mg/Kg 및 10 mg/Kg을 4주간 구강투여 후 모발 상태를 확인하였다. 도 8에 나타낸 바와 같이 난소가 절제된 동물(ovariectomized rat, OVX)에서는 제모된 털은 자라지 않는 반면, 난소가 절제된 동물 (OVX)에 목서 추출물 5 mg/Kg 및 10 mg/Kg을 4주간 구강투여한 결과 난소를 절개하지 않고 후복부만 절개 후 제모된 동물 (Sham)에서의 수준과 동일하게 목서 추출물에 의한 모발 성장 효과를 보였다.In order to create an animal similar to hair loss and hair growth inhibition caused by changes in sex hormones that occur after menopause in humans, 5 mg/Kg and 10 mg/Kg of woody extract was orally administered to a menopausal animal model after ovariectomy of experimental animals for 4 weeks, followed by oral administration of 5 mg/Kg and 10 mg/Kg to the hair. The status was checked. As shown in FIG. 8, the removed hair did not grow in ovariectomized rats (OVX), whereas 5 mg/Kg and 10 mg/Kg of wood extract were orally administered to ovariectomized rats (OVX) for 4 weeks. As a result, the hair growth effect due to the wood fern extract was shown to be the same as that in animals (Sham) whose hair was removed after incision of only the posterior abdomen without incision of the ovaries.
Claims (13)
A pharmaceutical composition for preventing or treating hair loss comprising an extract or fraction thereof.
The pharmaceutical composition for preventing or treating hair loss according to claim 1, wherein the plant is a flower, stem, leaf, fruit, root, or a combination thereof.
The pharmaceutical composition for preventing or treating hair loss according to claim 1, wherein the extract is extracted with water, C 1 to C 6 alcohol, or a mixed solvent thereof.
The pharmaceutical composition for preventing or treating hair loss according to claim 1, wherein the extract is extracted with an aqueous ethanol solution.
A health functional food for improving hair health containing extract or fractions thereof.
The method according to claim 5, wherein the plant is a flower, stem, leaf, fruit, root, or a combination thereof, a health functional food for improving hair health.
The method according to claim 5, wherein the extract is extracted with water, C 1 to C 6 alcohol, or a mixed solvent thereof, a health functional food for improving hair health.
The health functional food for improving hair health according to claim 5, wherein the extract is extracted with an aqueous ethanol solution.
A cosmetic composition for preventing hair loss and promoting hair growth comprising an extract or fraction thereof.
The cosmetic composition for preventing hair loss and promoting hair growth according to claim 9, wherein the plant is a flower, stem, leaf, fruit, root, or a combination thereof.
The cosmetic composition for preventing hair loss and promoting hair growth according to claim 9, wherein the extract is extracted with water, C 1 to C 6 alcohol, or a mixed solvent thereof.
The cosmetic composition for preventing hair loss and promoting hair growth according to claim 9, wherein the extract is extracted with an aqueous ethanol solution.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020220062876A KR20230163147A (en) | 2022-05-23 | 2022-05-23 | Composition for preventing or treating alopecia comprising extracts of Osmanthus fragrans |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020220062876A KR20230163147A (en) | 2022-05-23 | 2022-05-23 | Composition for preventing or treating alopecia comprising extracts of Osmanthus fragrans |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20230163147A true KR20230163147A (en) | 2023-11-30 |
Family
ID=88968528
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020220062876A KR20230163147A (en) | 2022-05-23 | 2022-05-23 | Composition for preventing or treating alopecia comprising extracts of Osmanthus fragrans |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20230163147A (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220003307A (en) | 2020-07-01 | 2022-01-10 | 고인연 | Method for manufacturing tofu and dried tofu therwith |
-
2022
- 2022-05-23 KR KR1020220062876A patent/KR20230163147A/en not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220003307A (en) | 2020-07-01 | 2022-01-10 | 고인연 | Method for manufacturing tofu and dried tofu therwith |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100950437B1 (en) | Herbal composition for the prevention of depilation and improvement of hair growth and method for preparing the same | |
KR101221417B1 (en) | Composition including ginseng berry extract for promoting hair growth | |
KR20210002005A (en) | Composition comprising extract of buckwheat sprout for strengthening hair root, activating hair growth or preventing alopecia | |
JP6709783B2 (en) | Composition for preventing hair loss or promoting hair growth containing alpine wormwood extract | |
KR20160023149A (en) | Composition comprising extract of herbal mixture for preventing alopecia or hair growth effect | |
JP6647292B2 (en) | Composition for preventing hair loss or promoting hair growth comprising Scutellaria alpina extract | |
KR101965594B1 (en) | Composition for prevention of losing hair or promotion of growing hair comprising bean extract | |
JP2013151437A (en) | Agent for enhancing differentiation from stem cell to brown adipocyte | |
KR100601903B1 (en) | Process for Preparing Wild Ginseng Cell | |
KR102353372B1 (en) | Composition for preventing hair loss or promoting hair growth comprising extract pupae of male bees | |
KR102557372B1 (en) | Composition for Preventing or Treating Hair Loss or Stimulating Hair Sprouting or Hair Growth Comprising Extracts of Rosa davurica Pall as Active Ingredient | |
KR102612017B1 (en) | Composition for skin improvement comprising multiple extract | |
KR20230163147A (en) | Composition for preventing or treating alopecia comprising extracts of Osmanthus fragrans | |
TWI706792B (en) | Use of skunk cabbage extract or its fraction | |
KR101702621B1 (en) | Anti-inflammatory agent containing phlox subulata extract | |
KR20170065956A (en) | A composition comprising bark of Cinnamomum loureirii extract having anti-oxidative or anti-inflammatory activity | |
KR20200084846A (en) | A composition for promoting the differentiation of human adipose derived stem cell | |
TW202102239A (en) | Antiaging agent, antioxidant, antiinflammatory agent and whitening agent, and cosmetic | |
KR100554947B1 (en) | Cosmetic composition comprising crude drug extract for preventing and improving baldness | |
KR102292114B1 (en) | Composition for Improving Skin Conditions Having Moisturizing, Anti-Inflammatory Caused by Fine Dust and Pore Shrinkage Property Comprising Plant Complex Extracts as Active Ingredient | |
KR102411893B1 (en) | Composition for inhibiting sebum secretion comprising Chestnut bur extract as an active ingredient | |
JP5866139B2 (en) | Pleurotus extract used in pharmaceutical and cosmetic compositions | |
KR102182710B1 (en) | Compositions for Skin Moisture Comprising Extract of Plectranthus tomentosa or Complex Extract thereof | |
KR20100094433A (en) | Composition comprising extracts of rubus coreanum miquel | |
KR101967919B1 (en) | Composition for preventing, improving or treating skin wrinkle comprising hexane fraction of Clerodendrum trichotomum extract or compound isolated from Clerodendrum trichotomum extract as effective component |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal |